Showing results (141-150 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|June 7, 2021
Health policy and public health implications of obesity in ChinaYoufa Wang, Li Zhao, Liwang Gao, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2020
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trialsJohannes F E Mann, Thomas Hansen, Thomas Idorn, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trialDavid C Wheeler, Bergur V Stefánsson, Niels Jongs, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trialGary Wittert, Karen Bracken, Kristy P Robledo, et al.
The Lancet. Diabetes & Endocrinology|December 21, 2020
Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control studyCari M Kitahara, Dagrun Slettebø Daltveit, Anders Ekbom, et al.
The Lancet. Diabetes & Endocrinology|December 28, 2020
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
The Lancet. Diabetes & Endocrinology|November 1, 2020
Insulin's centenary: the birth of an ideaRobert A Hegele, Grant M Maltman
The Lancet. Diabetes & Endocrinology|December 9, 2022
Continuous glucose monitoring and metrics for clinical trials: an international consensus statementTadej Battelino, Charles M Alexander, Stephanie A Amiel, et al.
The Lancet. Diabetes & Endocrinology|November 29, 2020
Diabetes, metabolic disease, and telomere lengthFeifei Cheng, Luke Carroll, Mugdha V Joglekar, et al.
Pageof 93